These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 21422148)

  • 1. The PhaSeal® system: impact of its use on workplace contamination and duration of chemotherapy preparation.
    Favier B; Labrosse H; Gilles-Afchain L; Cropet C; Perol D; Chaumard N; Latour JF; Hild P
    J Oncol Pharm Pract; 2012 Mar; 18(1):37-45. PubMed ID: 21422148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital.
    Miyake T; Iwamoto T; Tanimura M; Okuda M
    Springerplus; 2013 Dec; 2(1):273. PubMed ID: 23853750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance testing protocol for closed-system transfer devices used during pharmacy compounding and administration of hazardous drugs.
    Wilkinson AS; Allwood MC; Morris CP; Wallace A; Finnis R; Kaminska E; Stonkute D; Szramowska M; Miller J; Pengelly I; Hemingway M
    PLoS One; 2018; 13(10):e0205263. PubMed ID: 30379831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of the Use of a Closed System Drug Transfer Device on the Preparation Time of Anticancer Drugs].
    Nakashima T; Tsukiji K; Kubo A; Nishigaki R; Watabe D; Saito Y; Akagi T; Hashimoto H
    Yakugaku Zasshi; 2024; 144(8):815-821. PubMed ID: 39085058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cancer drug infusion devices prior to the implementation of a compounding robot.
    Caron G; Vasseur M; Courtin J; Masse M; Décaudin B; Genay S; Odou P; Simon N
    J Oncol Pharm Pract; 2024 Mar; 30(2):251-256. PubMed ID: 37203170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of an anticancer drug compounding robot in reducing the risks of manual preparation in a hospital pharmacy unit specialized in oncology.
    Cherif Chefchaouni A; Boudina Y; Chennaq M; Belahcen MJ; Rahali Y
    J Oncol Pharm Pract; 2023 Sep; 29(6):1334-1342. PubMed ID: 35938183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple and inexpensive method to monitor and minimize exposure from manipulation of cytotoxic drugs.
    Ali N; Carmo H; Robalo R; Rocha L; Fernandes C; Moreira F
    J Oncol Pharm Pract; 2024 Mar; 30(2):257-262. PubMed ID: 37151079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe Cytotoxic Drug Preparation Using Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal).
    Garrigue P; Montana M; Ventre C; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Int J Pharm Compd; 2016; 20(2):148-54. PubMed ID: 27323425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a closed-system drug transfer device (PhaSeal) and impact on preparation time.
    Sánchez-Rubio Ferrández J; Lozano MC; Iglesias I; Sánchez-Rubio Ferrández L; Rodríguez Vargas B; Moreno Díaz R
    Int J Pharm Compd; 2012; 16(5):431-3. PubMed ID: 23072203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study.
    Simon N; Vasseur M; Pinturaud M; Soichot M; Richeval C; Humbert L; Lebecque M; Sidikou O; Barthelemy C; Bonnabry P; Allorge D; Décaudin B; Odou P
    PLoS One; 2016; 11(7):e0159052. PubMed ID: 27391697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.
    Sessink PJ; Trahan J; Coyne JW
    Hosp Pharm; 2013 Mar; 48(3):204-12. PubMed ID: 24421463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator.
    Vyas N; Turner A; Clark JM; Sewell GJ
    J Oncol Pharm Pract; 2016 Feb; 22(1):10-9. PubMed ID: 25073678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Analysis of Using a Closed-System Transfer Device (CSTD) for Antineoplastic Drug preparation in a Malaysian Government-Funded Hospital.
    Chan HK; Lim YM
    Asian Pac J Cancer Prev; 2016 Nov; 17(11):4951-4957. PubMed ID: 28032722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal
    Kicenuik K; Northrup N; Dawson A; Locke J; Villamil JA; Chretin J; Sfiligoi G; Clifford C; Rosenberg M; Hamilton T; Regan R; Parsons-Doherty M; Mallett C; Philibert J; Impellizeri J; Hofmeister E
    Vet Comp Oncol; 2017 Mar; 15(1):163-173. PubMed ID: 25864458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupational exposure to anti-cancer drugs: A review of effects of new technology.
    Vyas N; Yiannakis D; Turner A; Sewell GJ
    J Oncol Pharm Pract; 2014 Aug; 20(4):278-87. PubMed ID: 23975555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leakage from closed-system transfer devices as detected by a radioactive tracer.
    De Ausen L; DeFreitas EF; Littleton L; Lustik M
    Am J Health Syst Pharm; 2013 Apr; 70(7):619-23. PubMed ID: 23515515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents.
    Clark BA; Sessink PJ
    J Oncol Pharm Pract; 2013 Jun; 19(2):99-104. PubMed ID: 23292973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operators.
    Fersing C; Deshayes E; Langlet S; Calas L; Lisowski V; Kotzki PO
    EJNMMI Radiopharm Chem; 2021 Jan; 6(1):2. PubMed ID: 33411035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.
    Gurusamy KS; Best LM; Tanguay C; Lennan E; Korva M; Bussières JF
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012860. PubMed ID: 29582940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.